ArticleDiscover oncology2025
A clinical analysis of 19 cases of chordomas with poor differentiation treated using diverse therapeutic modalities.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThere is an urgent need to enhance clinicians' ability to diagnose and treat chordomas with poor differentiation, particularly poorly differentiated chordomas (PDCs), through clinical case analysis.
methodsA retrospective review was conducted on the clinical data of 19 patients with pathologically confirmed chordomas with poor differentiation, treated at Hebei Yizhou Cancer Hospital between July 2021 and May 2024. All patients underwent surgery. 9 received proton radiation, with 4 also having conventional chemotherapy. 3 patients had both conventional chemotherapy and targeted therapy after proton radiation, while another 3 received chemotherapy, targeted therapy, and immunotherapy. The progression of the disease was primarily monitored through follow-up telephone consultations. The study used polytomous logistic regression to assess the impact of age and gender on chordoma lesion sites, and ordinal logistic regression to evaluate the effects of age, gender, and lesion sites on chordoma differentiation. The COX Proportional Hazards Model analyzed the influence of these factors and surgical resection ratio on chordoma prognosis. Kaplan-Meier survival analysis assessed the impact of surgical resection ratio on prognosis.
resultsPostoperative diagnoses revealed 12 cases of PDC, 4 of dedifferentiated chordoma (DDC), and 3 of low differentiated chordoma (LDC). Some patients experienced tumor reduction and symptom improvement. By August 2024, 8 patients had died, while 11 were still alive, with follow-up durations ranging from 12 to 65 months and an average of 29.45 months. Based on these limited 19 cases, COX regression analysis showed that sex, differentiation degrees, chordoma locations, treatment regimens, and surgical resection ratio were not independent prognostic factors (all P > 0.05). Younger age was linked to higher differentiation (P < 0.05), and chordomas on the clivus had the worst differentiation and highest malignancy (P < 0.001).
conclusionsBased on the analysis of 19 chordoma cases, it appears that for chordomas with poor differentiation, the completion of surgical resection followed by adjuvant chemotherapy, radiotherapy, and targeted therapy may enhance patient prognosis to some extent. The efficacy of immunotherapy for chordomas with poor differentiation warrants further investigation. Additionally, potential prognostic factors influencing chordoma outcomes should be validated in studies involving larger populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.